



**e-Therapeutics plc**  
("e-Therapeutics" or the "Company")

### **Board appoints Stephen Self to direct development**

**6 December 2010:** e-Therapeutics plc, the drug discovery and development company, today announce that Steve Self, Development Director, has agreed to join the Board as an Executive Director with immediate effect.

Steve began his career in Chemistry in 1975 with The Wellcome Foundation. He held a variety of positions in both R&D and Operations before being appointed as a full-time Project Manager in Wellcome Research in 1987. He became Head of Project management in 1991, and was appointed Group VP Project Management in 1993. Steve Joined Boots Healthcare International in 1995 as Head of Respiratory and Analgesic product development, before joining Merck Generics in 1997 as European Technical Director. He was appointed as Group R&D Director in 1999 and stayed with Merck until the sale of the company to Mylan in 2007. Since then he has worked for a private equity bank on major US pharmaceutical acquisitions.

Mr Self's primary responsibility will be to supervise the development of e-Therapeutics' proprietary portfolio of drug candidates. This involves complete Phase II trials of e-Therapeutics candidates in multiple metastatic cancers, depression and C.difficile plus possible Phase II trials for other anti-infective candidates. All the trials are planned to complete in 2012. Steve will use his considerable experience to deliver the trials and to ensure the highest quality data, suitable formulation, market positioning and the strongest intellectual property estate in each development project.

The additional information set out below is provided in accordance with the AIM Rules for new Board appointments.

Stephen Raymond Self, aged 56, is or has been a director or partner of the following companies/partnerships during the past five years:

KMS Therapeutics (current)

Mr. Self does not currently hold any ordinary shares in the Company. The Company has been informed by Mr. Self that there are no other matters required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules for Companies.

**Professor Malcolm Young, Chief Executive Officer of e-Therapeutics, said:**

"I am delighted to welcome Steve Self to our Board as we advance the lead candidates in our drug development portfolio and our proprietary drug discovery platform. Steve's experience of market-focused drug development is unsurpassed, and ideal for our portfolio. His hard-edged assessment of all the necessary facets of a successful drug candidate will greatly facilitate our aspirations for licensing and market launch of these assets."

**For more information, please contact:**

**e-Therapeutics plc**

Malcolm Young / John Cordiner  
Tel: +44 (0) 191 233 1317  
E-mail: malcolm@etherapeutics.co.uk  
www.etherapeutics.co.uk

**Panmure Gordon (UK) Limited**

Andrew Burnett / Aubrey Powell  
Tel: +44 (0) 20 7459 3600  
www.panmuregordon.com

**Notes for editors**

**About e-Therapeutics**

e-Therapeutics is a pioneering network pharmacology company focused on drug discovery and development. e-Therapeutics has a broad clinical pipeline that combines mid- and late-stage pharmaceutical products with earlier stage opportunities, all addressing important market sectors and unmet medical needs. e-Therapeutics' novel discovery and de-risking platform is becoming increasingly well validated, demonstrating far higher productivity than conventional platforms and enabling e-Therapeutics to continue to deliver many valuable new development candidates to its portfolio. E-Therapeutics, which has a strong IP position, is focused on the progression of its drug development programmes, securing strategically important licensing partners and broadening its pipeline with new, de-risked drug candidates.

Network pharmacology is a new paradigm in drug discovery. It is based on an accurate view of the interaction of drug molecules with networks of proteins inside and between cells. It uses information on these protein networks in diseased and normal cells; information about the full range of proteins that are affected by the presence of a molecule; and a validated computational technique to determine the impact of these interactions on these cells. This approach is now a feature of several of the major pharmaceutical companies' internal activities and interest in this area is growing rapidly. e-Therapeutics is based in the UK and India, with links to other companies and organisations across North America and South East Asia. For more information, please visit <http://www.etherapeutics.co.uk>.